It should be emphasized that the SRC/EST-1 signaling pathway could be a therapeutic target for both cisplatin-sensitive and resistant HNSCC, although our current study mainly focused on cisplatin-resistant HNSCC. This evidence concerns the gene SULT1E1 and head and neck squamous cell carcinoma.